Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Unlocking the potential of allogeneic Vδ2 T cells for ovarian cancer therapy through CD16 biomarker selection and CAR/IL-15 engineering

8 Nov 2023

Abstract excerpt

Abstract Allogeneic Vγ9Vδ2 (Vδ2) T cells have emerged as attractive candidates for developing cancer therapy due to their established safety in allogeneic contexts and inherent tumor-fighting capabilities. Nonetheless, the limited clinical success of Vδ2 T cell-based treatments may be attributed to donor variability, short-lived persistence, and tumor immune evasion. To address these constraints, we engineer Vδ2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immune Cell Function and Interaction
Share to T-cell and B-cell Immunology

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37938576
DOI: 10.1038/s41467-023-42619-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Unlocking the potential of allogeneic Vδ2 T cells for ovarian cancer therapy through CD16 biomarker selection and CAR/IL-15 engineeringPMID 37938576Read ↗

OPS-γδ: allogeneic opsonin-secreting γδT cell immunotherapy for solid tumours mediates direct and bystander immunitySemantic proximity Read ↗

CD161 Characterizes an Inflamed Subset of Cytotoxic T Lymphocytes Associated with Prolonged Survival in Human Papillomavirus–Driven Oropharyngeal CancerSemantic proximity Read ↗

Optimized Multiple Amplification Protocol for the Production of Allogeneic Human Vγ9Vδ2 T Lymphocytes for Adoptive Cell Transfer ImmunotherapySemantic proximity Read ↗

The quest continues: Human CD4 <sup>+</sup> CD16 <sup>+</sup> CD56 <sup>+</sup> ‘exTreg’ resemble NKT cells insteadSemantic proximity Read ↗

Single-cell RNA sequencing of human double-negative T cells reveals a favorable cellular signature for cancer therapySemantic proximity Read ↗

Dasatinib boosts γδ T cell expansion and memory phenotypes with enhanced antitumor immunity.Semantic proximity Read ↗

Human γδ T cells in the tumor microenvironment: Key insights for advancing cancer immunotherapySemantic proximity Read ↗

Vγ9Vδ2 T Cells Concurrently Kill Cancer Cells and Cross-Present Tumor AntigensSemantic proximity Read ↗

IL-21 promotes the expansion of CD27+ CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells.Semantic proximity Read ↗

FCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical RelevanceSemantic proximity Read ↗

CDR3δ -grafted γ9δ2T cells mediate effective antitumor reactivity.Semantic proximity Read ↗

Increased frequency of CD4+ cells expressing CD161 in cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.